Infection Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Fourth Department of Liver Disease (Difficult & Complicated Liver Diseases and Artificial Liver Center), Beijing You'an Hospital Affiliated to Capital Medical University, Beijing, China.
Braz J Med Biol Res. 2022 Oct 17;55:e12040. doi: 10.1590/1414-431X2022e12040. eCollection 2022.
Naringin (Nar) has been reported to exert potential hepatoprotective effects against acetaminophen (APAP)-induced injury. Mitochondrial dysfunction plays an important role in APAP-induced liver injury. However, the protective mechanism of Nar against mitochondrial damage has not been elucidated. Therefore, the aim of this study was to investigate the hepatoprotective effects of Nar against APAP and the possible mechanisms of actions. Primary rat hepatocytes and HepG2 cells were utilized to establish an in vitro model of APAP-induced hepatotoxicity. The effect of APAP and Nar on cell viability was evaluated by a CCK8 assay and detection of the concentrations of alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase. The cellular concentrations of biomarkers of oxidative stress were measured by ELISA. The mRNA expression levels of APAP-related phase II enzymes were determined by real-time PCR. The protein levels of Nrf2, phospho (p)-AMPK/AMPK, and biomarkers of mitochondrial dynamics were determined by western blot analysis. The mitochondrial membrane potential (MMP) was measured by high-content analysis and confocal microscopy. JC-1 staining was performed to evaluate mitochondrial depolarization. Nar pretreatment notably prevented the marked APAP-induced hepatocyte injury, increases in oxidative stress marker expression, reductions in the expression of phase II enzymes, significant loss of MMP, mitochondrial depolarization, and mitochondrial fission in vitro. In conclusion, Nar alleviated APAP-induced hepatocyte and mitochondrial injury by activating the AMPK/Nrf2 pathway to reduce oxidative stress in vitro. Applying Nar for the treatment of APAP-induced liver injury might be promising.
柚皮苷(Nar)已被报道具有对抗对乙酰氨基酚(APAP)诱导损伤的潜在肝保护作用。线粒体功能障碍在 APAP 诱导的肝损伤中起重要作用。然而,Nar 对抗线粒体损伤的保护机制尚未阐明。因此,本研究旨在探讨 Nar 对 APAP 的肝保护作用及其可能的作用机制。原代大鼠肝细胞和 HepG2 细胞被用于建立 APAP 诱导的肝毒性体外模型。通过 CCK8 测定和检测丙氨酸氨基转移酶、天冬氨酸氨基转移酶和乳酸脱氢酶的浓度来评估 APAP 和 Nar 对细胞活力的影响。通过 ELISA 测量氧化应激生物标志物的细胞浓度。通过实时 PCR 测定 APAP 相关 II 相酶的 mRNA 表达水平。通过 Western blot 分析测定 Nrf2、磷酸化(p)-AMPK/AMPK 和线粒体动力学生物标志物的蛋白水平。通过高内涵分析和共聚焦显微镜测量线粒体膜电位(MMP)。通过 JC-1 染色评估线粒体去极化。Nar 预处理显著防止了体外明显的 APAP 诱导的肝细胞损伤、氧化应激标志物表达增加、II 相酶表达减少、MMP 显著丧失、线粒体去极化和线粒体分裂。总之,Nar 通过激活 AMPK/Nrf2 通路减轻 APAP 诱导的肝细胞和线粒体损伤,从而减少体外氧化应激。应用 Nar 治疗 APAP 诱导的肝损伤可能是有前途的。